<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>For more than two decades the French-American-British (FAB) classification has provided a framework for the diagnosis and classification of the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, with widespread use of this classification, it became clear that prognostic differences existed within single categories </plain></SENT>
<SENT sid="2" pm="."><plain>The FAB classification has therefore been modified by a World Health Organization (WHO) expert group to take account of these prognostic differences </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, therapy-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> and the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> have been recognized as distinct types of disorder and the existence of mixed myelodysplastic/<z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> has been recognized; <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath>, previously regarded as one of the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, was re-assigned to this latter group of disorders </plain></SENT>
</text></document>